Thalassaemic trait and systemic lupus erythematosus

Abstract

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial.

Systemic lupus erythematosus with sickle cell/β0‐thalassemia

“…The incidence of haemoglobinopathies in patients with SLE has not been found to be significantly different from that in the general population 4 . However, the prevalence of central nervous system involvement, renal disease and persistently low complement fractions have been reported in a greater frequency with coexisting beta thalassemia and SLE 4 .…”

“…The incidence of haemoglobinopathies in patients with SLE has not been found to be significantly different from that in the general population 4 . However, the prevalence of central nervous system involvement, renal disease and persistently low complement fractions have been reported in a greater frequency with coexisting beta thalassemia and SLE 4 . The postulated mechanisms have been the hypercoaguable state in thalassemia, 5 homocystinemia, 6 the decreased binding of immune complexes in thalassemia, 4 and a defect in the alternative complement pathway in SCD 7 .…”

“…However, the prevalence of central nervous system involvement, renal disease and persistently low complement fractions have been reported in a greater frequency with coexisting beta thalassemia and SLE 4 . The postulated mechanisms have been the hypercoaguable state in thalassemia, 5 homocystinemia, 6 the decreased binding of immune complexes in thalassemia, 4 and a defect in the alternative complement pathway in SCD 7 . The symptomatic overlap between SLE and haemoglobinopathies can make the diagnosis and management of exacerbations of disease activity challenging.…”

Nephritis, Neuropsychiatric Lupus in Sickler Patient: A Case Report

“…Anemia is a common presentation for lupus patients occur with different types and severity, but rarely associated with haemoglobinopathies, hematologic manifestations of SLE are variable [13], lupus patient may have leucopenia, lymphopenia, thrombocytopenia, autoimmune hemolytic anemia (AIHA), which are included in classification criteria of SLE, Thrombotic Thrombocytopenic Purpura (TTP), and myelofibrosis which are not included in SLE classification criteria [14]. Few SLE patients were reported in literature with severe lupus associated with β thalassemia which is rare association.…”

Could Heterozygous Beta Thalassemia Provide Protection Against Multiple Sclerosis?

“…For example, the prevalence of HBT is significantly increased in rheumatoid arthritis patients; similarly, the incidence of rheumatoid arthritis is increased in HBT patients compared to the general population [2]. The prevalence of HBT in systemic lupus erythematosus (SLE) patients was lower than that in the general population, but SLE has been reported to exhibit a more serious course in subjects with HBT [4,5]. The causes of these associations remain unknown.…”